Nurse navigators and APPs are key members of the multidisciplinary team who can lead and implement QI efforts to ensure timely and effective biomarker testing for patients with early-stage NSCLC.
The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of zenocutuzumab for NRG1-positive lung and pancreatic cancer. The FDA extended the ...
Surveyed individuals who identified as a racial or ethnic minority reported difficulties discussing cancer diagnosis and treatment. Typical stories shared about “going flat” after a mastectomy may not ...